Resources
Explore our resources page, a hub of valuable content supporting our science and technology.
News
Articles, press releases, industry coverage and commentary.
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
SEATTLE, W.A., July 9, 2024 -- Pluristyx, a leading provider
Pluristyx launches PluriFreeze™ Cryopreservation Media to Accelerate Stem Cell Therapy Development
Seattle, WA April 3, 2024 – Pluristyx, a leading provider
BioCentriq Strengthens Partnership with Pluristyx to Accelerate the Development of iPSC-Derived NK Cell Therapies
Newark, New Jersey March 7, 2024 BioCentriq, Inc., a global
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
The addition of ES cells and iPSCs will enhance Charles
Pluristyx and Resilience Form Partnership to Accelerate the Development of Promising Stem Cell Therapies
Pluristyx, Inc., with expertise in gene-edited induced pluripotent stem cells
Webinars & Videos
View our curated collection of webinars and videos.
The Next Big Thing in Pharma
Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, talks to Pharma’s Almanac about pluripotent stem cells and how the company speeds up the R&D process by delivering Ready to Differentiate® cells.
A Safe Way of Cloaking Cells to Evade the Immune System (Dr. Andras Nagy)
A Safe Way of Cloaking Cells to Evade the Immune System | Andras Nagy, PhD, HonD, FRSC, Senior Investigator| Lunenfeld-Tanenbaum Research Institute, Sinai Health System; 25 Orde St, 5th floor, room 5-1015 | Toronto, ON, M5T 3H7 | Canada Video recording of Dr. Andras Nagy speaking at the ISCT (International Society of Cell& Gene Therapy) 2023 Annual Meeting
panCELLa FailSafe®
MAKING CELL THERAPY SAFE: Cell therapies are largely derived from
A Failsafe® suicide gene-based system to improve safety & standardization of neural grafts (Parish)
Professor Clare Parish BBiomedSci, PhD; NHMRC Senior Research Fellow; Stem
Publications
Explore our comprehensive compilation of scientific publications.
Transplantation of Human Cortically-Specified Neuroepithelial Progenitor Cells Leads to Improved Functional Outcomes in a Mouse Model of Stroke.
Islam R, Drecun S, Varga BV, Vonderwalde I, Siu R, Nagy A and Morshead CM (2021) Front. Cell. Neurosci. 15:654290. doi:10.3389/fncel.2021.654290
Synaptic Dysfunction in Human Neurons With Autism-Associated Deletions in PTCHD1-AS
Ross PJ, Zhang WB, Mok RSF, Zaslavsky K, Deneault E, D’Abate L, Rodrigues DC, Yuen RKC, Faheem M, Mufteev M, Piekna A, Wei W, Pasceri P, Landa RJ, Nagy A, Varga
Initial cell maturity changes following transplantation in a hyaluronan-based hydrogel and impacts therapeutic success in the stroke-injured rodent brain.
Payne SL, Tuladhar A, Obermeyer JM, Varga BV, Teal CJ, Morshead CM, Nagy A, Shoichet MS (2019). Biomaterials. 2019 Feb;192:309-322. doi:10.1016/j.biomaterials.2018.11.020. Epub 2018 Nov 15. PMID: 30468998
Blog
Pluristyx blog articles and further resources to assist with your iPSC-based cell therapy development.
Cryopreservation (II): Cutting edge solutions
Introduction to Cryopreservation Cryopreservation, involving the preservation of cells and
FailSafe®: Engineered safety for tomorrow’s cell therapies
Chimeric antigen receptor (CAR) T-cell therapies are a novel class
Cryopreservation
Introduction to Cryopreservation Cryopreservation describes the controlled process of freezing